PURPOSE: The proapoptotic receptors tumor necrosis factor--related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and TRAIL-R2 are targets of drugs in clinical development, and receptor expression levels may be important determinants of sensitivity to receptor agonists. We assessed TRAIL-R1 and TRAIL-R2 expression patterns in a large cohort of melanomas and benign nevi. EXPERIMENTAL DESIGN: We analyzed tissue microarrays containing 546 melanomas and 540 nevi using our automated quantitative method to measure protein levels in situ (AQUA). The system uses S100 to define pixels as melanoma (tumor mask) within the array spot and measures intensity of TRAIL-receptor expression using Cy5-conjugated antibodies within the mask. AQUA scores were correlated with clinical and pathologic variables. RESULTS: TRAIL-R1 and TRAIL-R2 expression was higher in melanomas than in nevi (P < 0.0001), and higher in primary than in metastatic specimens (P = 0.0031 and P < 0.0001, respectively). TRAIL-R1 and TRAIL-R2 expression exceeding the 95th percentile for nevi was found in 19% and 74% of melanoma specimens, respectively. Although on univariate analysis, high TRAIL-R2 expression correlated with increased survival (P = 0.0439), it was not associated with survival within the primary or metastatic subcohorts. TRAIL-R1 expression was not associated with survival. CONCLUSIONS: TRAIL-R1 and TRAIL-R2 expression is higher in malignant melanocytes than in their benign counterparts, suggesting that these receptors might be effective therapeutic targets in melanoma. Expression is higher in early-stage disease than in metastatic specimens, and expression exceeding that found in nevi is found in a substantially larger fraction of melanomas for TRAIL-R2 compared with TRAIL-R1. Assessment of baseline tumor TRAIL receptor expression may be important in analysis of clinical trials involving TRAIL receptor agonists.
PURPOSE: The proapoptotic receptors tumor necrosis factor--related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and TRAIL-R2 are targets of drugs in clinical development, and receptor expression levels may be important determinants of sensitivity to receptor agonists. We assessed TRAIL-R1 and TRAIL-R2 expression patterns in a large cohort of melanomas and benign nevi. EXPERIMENTAL DESIGN: We analyzed tissue microarrays containing 546 melanomas and 540 nevi using our automated quantitative method to measure protein levels in situ (AQUA). The system uses S100 to define pixels as melanoma (tumor mask) within the array spot and measures intensity of TRAIL-receptor expression using Cy5-conjugated antibodies within the mask. AQUA scores were correlated with clinical and pathologic variables. RESULTS:TRAIL-R1 and TRAIL-R2 expression was higher in melanomas than in nevi (P < 0.0001), and higher in primary than in metastatic specimens (P = 0.0031 and P < 0.0001, respectively). TRAIL-R1 and TRAIL-R2 expression exceeding the 95th percentile for nevi was found in 19% and 74% of melanoma specimens, respectively. Although on univariate analysis, high TRAIL-R2 expression correlated with increased survival (P = 0.0439), it was not associated with survival within the primary or metastatic subcohorts. TRAIL-R1 expression was not associated with survival. CONCLUSIONS:TRAIL-R1 and TRAIL-R2 expression is higher in malignant melanocytes than in their benign counterparts, suggesting that these receptors might be effective therapeutic targets in melanoma. Expression is higher in early-stage disease than in metastatic specimens, and expression exceeding that found in nevi is found in a substantially larger fraction of melanomas for TRAIL-R2 compared with TRAIL-R1. Assessment of baseline tumor TRAIL receptor expression may be important in analysis of clinical trials involving TRAIL receptor agonists.
Authors: Levi A Garraway; Hans R Widlund; Mark A Rubin; Gad Getz; Aaron J Berger; Sridhar Ramaswamy; Rameen Beroukhim; Danny A Milner; Scott R Granter; Jinyan Du; Charles Lee; Stephan N Wagner; Cheng Li; Todd R Golub; David L Rimm; Matthew L Meyerson; David E Fisher; William R Sellers Journal: Nature Date: 2005-07-07 Impact factor: 49.962
Authors: Robert F Kelley; Klara Totpal; Stephanie H Lindstrom; Mary Mathieu; Karen Billeci; Laura Deforge; Roger Pai; Sarah G Hymowitz; Avi Ashkenazi Journal: J Biol Chem Date: 2004-11-01 Impact factor: 5.157
Authors: Kyle A Divito; Aaron J Berger; Robert L Camp; Marisa Dolled-Filhart; David L Rimm; Harriet M Kluger Journal: Cancer Res Date: 2004-12-01 Impact factor: 12.701
Authors: Aaron J Berger; Robert L Camp; Kyle A Divito; Harriet M Kluger; Ruth Halaban; David L Rimm Journal: Cancer Res Date: 2004-12-01 Impact factor: 12.701
Authors: Donald J Buchsbaum; Tong Zhou; William E Grizzle; Patsy G Oliver; Charlotte J Hammond; Sijian Zhang; Mark Carpenter; Albert F LoBuglio Journal: Clin Cancer Res Date: 2003-09-01 Impact factor: 12.531
Authors: L Pukac; P Kanakaraj; R Humphreys; R Alderson; M Bloom; C Sung; T Riccobene; R Johnson; M Fiscella; A Mahoney; J Carrell; E Boyd; X T Yao; L Zhang; L Zhong; A von Kerczek; L Shepard; T Vaughan; B Edwards; C Dobson; T Salcedo; V Albert Journal: Br J Cancer Date: 2005-04-25 Impact factor: 7.640
Authors: Harriet M Kluger; Mary M McCarthy; Ayesha B Alvero; Mario Sznol; Stephan Ariyan; Robert L Camp; David L Rimm; Gil Mor Journal: J Transl Med Date: 2007-01-26 Impact factor: 5.531
Authors: Harriet M Kluger; Christopher R Zito; Meaghan L Barr; Marina K Baine; Veronica L S Chiang; Mario Sznol; David L Rimm; Lieping Chen; Lucia B Jilaveanu Journal: Clin Cancer Res Date: 2015-03-18 Impact factor: 12.531
Authors: Lucia B Jilaveanu; Maneka Puligandla; Sarah A Weiss; Xin Victoria Wang; Christopher Zito; Keith T Flaherty; Marta Boeke; Veronique Neumeister; Robert L Camp; Adebowale Adeniran; Michael Pins; Judith Manola; Robert S DiPaola; Naomi B Haas; Harriet M Kluger Journal: Clin Cancer Res Date: 2017-10-24 Impact factor: 12.531
Authors: Harriet M Kluger; Christopher R Zito; Gabriela Turcu; Marina K Baine; Hongyi Zhang; Adebowale Adeniran; Mario Sznol; David L Rimm; Yuval Kluger; Lieping Chen; Justine V Cohen; Lucia B Jilaveanu Journal: Clin Cancer Res Date: 2017-02-21 Impact factor: 12.531
Authors: Janice M Mehnert; Mary M McCarthy; Lucia Jilaveanu; Keith T Flaherty; Saadia Aziz; Robert L Camp; David L Rimm; Harriet M Kluger Journal: Hum Pathol Date: 2009-12-11 Impact factor: 3.466
Authors: Lucia Jilaveanu; Christopher Zito; Sandra J Lee; Katherine L Nathanson; Robert L Camp; David L Rimm; Keith T Flaherty; Harriet M Kluger Journal: Clin Cancer Res Date: 2009-02-01 Impact factor: 12.531
Authors: Saadia A Aziz; Michael Davies; Elah Pick; Christopher Zito; Lucia Jilaveanu; Robert L Camp; David L Rimm; Yuval Kluger; Harriet M Kluger Journal: Clin Cancer Res Date: 2009-04-21 Impact factor: 12.531